...
首页> 外文期刊>Analytical methods >Microfluidic devices for label-free and non-instrumented quantitation of unamplified nucleic acids by flow distance measurement
【24h】

Microfluidic devices for label-free and non-instrumented quantitation of unamplified nucleic acids by flow distance measurement

机译:通过流动距离测量对未扩增核酸进行无标记和非仪器定量的微流体装置

获取原文
获取原文并翻译 | 示例
           

摘要

Timely biomarker quantitation has potential to improve human health but current methods have disadvantages either in terms of cost and complexity for benchtop instruments, or reduced performance in quantitation and/or multiplexing for point-of-care systems. We previously developed microfluidic devices wherein visually observed flow distances correlated with a model analyte's concentration (Chatterjee et at, Anal. Chem., 2012, 84, 7057). Here, we significantly expand over this prior result to demonstrate the measurement of unamplified DNA analogues of microRNAs (miRNAs), biomarkers whose levels can be altered in disease states. We have developed a method for covalently attaching nucleic acid receptors on poly(dimethylsiloxane) microchannelsurfaces by silane and cross-linker treatments. We found a flow distance dependence on target concentrations from 10 μg mL~(-1) to 10 pg mL~(-1) for DNA in both buffer and synthetic urine. Moreover, flow time in addition to flow distance is correlated with target concentration. We also observed longer flow distances for single-base mismatches compared to the target sequence at the same concentration, indicating that our approach can be used to detect point mutations. Finally, experiments with DNA analogues of miRNA biomarkers for kidney disease (mir-200c-3p) and prostate cancer (mir-107) in synthetic urine showed the ability to detect these analytes near clinically relevant levels. Our results demonstrate that these novel microfluidic assays offer a simple route to sensitive, amplification-free nucleic acid quantitation, with strong potential for point-of-care application.
机译:及时的生物标志物定量具有改善人类健康的潜力,但是目前的方法在台式仪器的成本和复杂性方面或在即时点系统的定量和/或多路复用性能降低方面均具有缺点。我们先前开发了微流体装置,其中目视观察到的流动距离与模型分析物的浓度相关(Chatterjee等人,Anal。Chem。,2012,84,7057)。在这里,我们大大扩展了这个先前的结果,以证明未扩增的microRNA(miRNA)DNA类似物的测量,miRNA是在疾病状态下其水平可以改变的生物标志物。我们已经开发了一种通过硅烷和交联剂处理将核酸受体共价附着在聚(二甲基硅氧烷)微通道表面上的方法。我们发现缓冲液和合成尿液中DNA的目标浓度从10μgmL〜(-1)到10 pg mL〜(-1)的流动距离依赖性。此外,除了流动距离以外的流动时间还与目标浓度相关。我们还观察到与相同浓度下的靶序列相比,单碱基错配的流动距离更长,这表明我们的方法可用于检测点突变。最后,针对合成尿液中的肾脏疾病(mir-200c-3p)和前列腺癌(mir-107)的miRNA生物标志物的DNA类似物进行的实验表明,能够检测接近临床相关水平的这些分析物。我们的结果表明,这些新颖的微流体测定法为灵敏,无扩增的核酸定量提供了一条简单的途径,对于即时医疗应用具有强大的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号